Search results
Showing 481 to 492 of 492 results for %s
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
NICE responds to publication of the government's Life Sciences Sector Plan
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
Public consultation on updates to health technology evaluations manual
A public consultation marking the first update to NICE's health technology evaluations manual is now open.
NICE announces proposals to transform its HealthTech programme to drive more technology into the NHS
Consultation launches on the biggest shake-up of NICE's HealthTech programme to date.
NICE Board says new method allowing greater weight to be given to severe diseases is working
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
More than 1,000 people each year will benefit from NICE's recommendation.
How we can offer a broader range of benefits for people, their families and carers
NICE has been part of a research project investigating how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health.
Harriet Unsworth outlines her role in updating our evidence standards framework for digital health technologies. She also explains how you can share your views as part of our consultation.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use